Pharmacokinetics and Safety of a New Paediatric Fixed-Dose Combination of Zidovudine/Lamivudine/Nevirapine in HIV-Infected Children
- 1 November 2011
- journal article
- research article
- Published by SAGE Publications in Antiviral Therapy
- Vol. 16 (8) , 1287-1295
Abstract
Background: Alternatives to the available stavudine-containing paediatric fixed-dose combination (FDC) tablets are rapidly needed due to concerns regarding the cumulative toxicity of long-term stavudine exposure. We report the bioavailability and short-term safety of a novel paediatric FDC tablet of zidovudine (ZDV)/lamivudine (3TC)/nevirapine (NVP; 30/15/28 mg) in HIV-infected children. Methods: In this Phase I/II open-label pharmacokinetic study, 42 children weighing 6–30 kg treated with NVP-based HAART for ≥4 weeks were randomized to receive the FDC tablets (GPO-VIR Z30) or the liquid formulations. Dosing was weight-based. Intensive 12-h blood sampling was performed after 2 weeks; subjects then crossed-over to the alternate formulation at equal doses and sampling repeated 2 weeks later. Pharmacokinetic parameters were determined by non-compartmental analysis. Buccal-swab samples were collected for cytochrome P450 ( CYP)2B6 polymorphism analysis. Results: With the FDC tablet, the geometric mean (90% CI) area under the curve (AUC) for ZDV, 3TC and NVP was 1.58 (1.49-1.68), 7.78 (7.38-8.19) and 68.88 (62.13-76.36) μg•h/ml, respectively. Rules for NVP therapeutic inadequacy were defined a priori, and despite lower NVP exposure with the tablet ( P <0.001), the levels remained therapeutically adequate. ZDV AUC was similar between formulations. 3TC exposure was significantly higher with the tablet but comparable to historical data in adults and children taking branded tablets. While receiving the tablet, NVP AUC in children with CYP2B 516 GG (45%), GT (45%) and TT (10%) genotypes were 67.0, 74.5 and 106.4 μg•h/ml, respectively ( P =0.04). Conclusions: Disparities in drug exposure between formulations were observed; however, the FDC tablet delivered therapeutically adequate exposures of each drug and could well play an important role in simplifying antiretroviral treatment for children.Keywords
This publication has 26 references indexed in Scilit:
- Nevirapine Exposure with WHO Pediatric Weight Band Dosing: Enhanced Therapeutic Concentrations Predicted Based on Extensive International Pharmacokinetic ExperienceAntimicrobial Agents and Chemotherapy, 2012
- Pharmacokinetics of lamivudine, abacavir and zidovudine administered twice daily as syrups versus scored tablets in HIV‐1‐infected Ugandan childrenJournal of the International AIDS Society, 2010
- A Chewable Pediatric Fixed-dose Combination Tablet of Stavudine, Lamivudine, and NevirapineThe Pediatric Infectious Disease Journal, 2010
- Cytochrome P450 2B6 516G→T is associated with plasma concentrations of nevirapine at both 200 mg twice daily and 400 mg once daily in an ethnically diverse populationHIV Medicine, 2009
- EFFICACY OF NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR-BASED HIGHLY ACTIVE ANTIRETROVIRAL THERAPY IN THAI HIV-INFECTED CHILDREN AGED TWO YEARS OR LESSThe Pediatric Infectious Disease Journal, 2009
- Nevirapine, stavudine and lamivudine pharmacokinetics in African children on paediatric fixed-dose combination tabletsAIDS, 2008
- SUSTAINED IMMUNOLOGIC AND VIROLOGIC EFFICACY AFTER FOUR YEARS OF HIGHLY ACTIVE ANTIRETROVIRAL THERAPY IN HUMAN IMMUNODEFICIENCY VIRUS INFECTED CHILDREN IN THAILANDThe Pediatric Infectious Disease Journal, 2007
- Pharmacokinetic comparison of generic and trade formulations of lamivudine, stavudine and nevirapine in HIV-infected Malawian adultsAIDS, 2007
- Quality Assurance Program for Pharmacokinetic Assay of Antiretrovirals: ACTG Proficiency Testing for Pediatric and Adult Pharmacology Support Laboratories, 2003 to 2004Therapeutic Drug Monitoring, 2006
- Comparison of the Plasma Pharmacokinetics of Lamivudine During Twice and Once Daily Administration in Patients with HIVClinical Pharmacokinetics, 2001